The Claim
Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with greater weight loss than placebo in adults, with non-diabetic individuals achieving approximately 15.7% reduction in body weight at 12 months compared to 5.1% in diabetic individuals, based on pooled data from 56,580 patients across 45 studies.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
GLP-1 receptor agonists, a class of diabetes drugs, lead to more weight loss than placebo. In a large analysis of 45 studies with over 56,000 people, those without type 2 diabetes lost about 15.7% of their body weight in 12 months, while those with diabetes lost about 5.1%.
See the scientific wording
Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with greater weight loss than placebo in adults with and without type 2 diabetes, with non-diabetic individuals achieving approximately 15.7% reduction in body weight at 12 months compared to 5.1% in diabetic individuals, based on pooled data from 56,580 patients across 45 studies.
GLP-1 medicines make your brain feel full, your body release insulin when needed, and slow down how fast food leaves your stomach. This helps you eat less and use energy better, causing weight loss.
What the research says
1 studyThe study found that people without diabetes lost about 15.7% of their body weight after one year on GLP-1 medications, while people with diabetes lost about 5.1%, and both groups lost more weight than those on a placebo.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.